HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update

HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of 430 million KRW. Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expected in November 2024. ROCKVILLE, Md. and SEOUL,...